
Absci Corp (ABSI) Stock Forecast & Price Target
Absci Corp (ABSI) Analyst Ratings
Bulls say
Absci is a leading AI-powered synthetic biology company that has a clear competitive advantage in the drug discovery process through its integrated platform. With its lead product candidate, ABS-201, showing promising results in its Phase 1 trial, there is a high likelihood of successful efficacy readouts in the near future. Additionally, the company's solid financial standing, with $201 million in cash as of 2Q:26, and partnerships with major pharmaceutical companies like Eli Lilly, further supports a positive outlook for the company.
Bears say
Absci is a biotechnology company utilizing artificial intelligence and synthetic biology to expand the therapeutic potential of proteins. Despite promising data from peer companies in the same field, Absci's lead product candidate, ABS-201, is still in early stages of development and may face hurdles in gaining regulatory approval. Additionally, Absci's pipeline and platform are also in early stages, with no guarantee of success in the clinic, leading to a negative outlook for the company's stock.
This aggregate rating is based on analysts' research of Absci Corp and is not a guaranteed prediction by Public.com or investment advice.
Absci Corp (ABSI) Analyst Forecast & Price Prediction
Start investing in Absci Corp (ABSI)
Order type
Buy in
Order amount
Est. shares
0 shares